For a better experience of our website please update you web browser from IE11 to Microsoft Edge or an alternative modern browser such as Google Chrome. Thank you.

Jubilant Biosys Logo

Your global leading partner in science for end to end CRDMO services

Leadership Team

Serena Lugli

Serena Lugli

Vice President - Project Management, CRDMO

Serena brings over 20 years of experience in Project Management in the international pharmaceutical industry from drug discovery and development to CRO and CDMO businesses.

Prior to joining Jubilant, Serena has held various leadership roles throughout her career working with major pharmaceutical companies encompassing DuPont Pharmaceuticals, GlaxoSmithKline (GSK), Hoffmann La Roche, Aptuit (CRO) and Fabbrica Italiana Sintetici (CDMO).

While at DuPont Pharmaceuticals, GSK, and Hoffmann La Roche Serena was involved in the management of several drug discovery and clinical development programs in the therapeutic areas of inflammation, oncology, rare disease and neuroscience.

At Aptuit Serena managed key client relationships with regards to the operational/delivery aspects of their projects. Both at Aptuit and Hoffmann La Roche Serena had the opportunity to lead and develop a group of Project Managers.

Fabbrica Italiana Sintetici (FIS) gave Serena the opportunity to start-up and manage an R&D business unit dedicated to the development of new generic APIs. Subsequently FIS promoted Serena to develop and lead the company-wide Project Management function. Her key achievements were the implementation of a Project and Portfolio Management structure aimed to improve the execution of the CDMO business with respect to on time and on cost delivery to customers. Serena and her team managed a portfolio of over 40 projects from process development to validation and start of commercial production.

In addition to her PhD studies in the field of immunology held at the Swiss Federal Institute of Technology in Zurich, Switzerland, Serena also has post-doctoral experience in oncology research from the Dana Farber Cancer Institute, Harvard Medical School in Boston, US.

Contact-icon

GET IN TOUCH